Technical Analysis for ADPT - Adaptive Biotechnologies Corporation

Grade Last Price % Change Price Change
grade B 46.1 -3.58% -1.71
ADPT closed down 3.58 percent on Friday, August 16, 2019, on 82 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A N/A Up
See historical ADPT trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup -3.58%
Wide Range Bar Range Expansion -3.58%
Upper Bollinger Band Walk Strength -3.58%
Above Upper BB Strength -3.58%
Overbought Stochastic Strength -3.58%

Older signals for ADPT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Cancer Diseases Infectious Diseases Cancers Drug Discovery Diagnostic Tests Leukemia
Is ADPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 51.0
52 Week Low 34.11
Average Volume 741,482
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 40.1695
10-Day Moving Average 41.431
Average True Range 3.0344
ADX 28.03
+DI 29.1831
-DI 18.0588
Chandelier Exit (Long, 3 ATRs ) 39.3968
Chandelier Exit (Short, 3 ATRs ) 43.2132
Upper Bollinger Band 46.3458
Lower Bollinger Band 33.9932
Percent B (%b) 0.98
BandWidth 30.751192
MACD Line 1.4957
MACD Signal Line 0.5042
MACD Histogram 0.9915
Fundamentals Value
Market Cap 5.55 Billion
Num Shares 120 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -315.75
Price-to-Sales 4.89
Price-to-Book 0.91
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 49.90
Resistance 3 (R3) 50.13 49.09 49.26
Resistance 2 (R2) 49.09 48.13 48.98 49.05
Resistance 1 (R1) 47.60 47.53 47.08 47.37 48.84
Pivot Point 46.56 46.56 46.31 46.45 46.56
Support 1 (S1) 45.07 45.60 44.55 44.84 43.36
Support 2 (S2) 44.03 45.00 43.92 43.15
Support 3 (S3) 42.54 44.03 42.94
Support 4 (S4) 42.31